The aim of the current study is to investigate the effects of a bacterial formulation, which is effective on hypothalamus-hypophysis axis, and a prebiotic, which enhances the growth of thses bactrial strains (galactooligsaccharide), on depression and appetite score. Inclusion crateria: Melancolic type of major depression with mild to moderate level; consumption of one the fallowing anti-depressant drugs: sertraline, fluoxetine and citalopram; range for ages 18 to 50 years. Exlusion crateria: people who have consumed probiotic products regularly 2 month before the intervention; Omega 3 and anti-oxidant supplements consumption 4-6 weeks befor the beginning of intervention and following a specific diet. The sample size of the study is 90. The participants randomly allocate into three groups. Each group intakes one of the following intervention for two months: probiotic supplement (containing Lactobacillus helveticus, Bifidobacterium longum), prebiotic supplement and placebo. The following outcomes will be measured: serum levels of free leptin, tryptophan, inflammatory factors (IL-6, IL_1β and TNF-α), fasting urinary level of cortisol, appetite and depression score.